JP5529534B2 - ４−ヒドロキシチオベンズアミド薬剤誘導体 - Google Patents

４−ヒドロキシチオベンズアミド薬剤誘導体 Download PDF

Info

Publication number
JP5529534B2
JP5529534B2 JP2009519765A JP2009519765A JP5529534B2 JP 5529534 B2 JP5529534 B2 JP 5529534B2 JP 2009519765 A JP2009519765 A JP 2009519765A JP 2009519765 A JP2009519765 A JP 2009519765A JP 5529534 B2 JP5529534 B2 JP 5529534B2
Authority
JP
Japan
Prior art keywords
compound
acid
mmol
thiocarbamoyl
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009519765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543811A5 (https=
JP2009543811A (ja
Inventor
ワレス、ジョン、エル．
シリノ、ギウゼッペ
サンタガーダ、ビンセンゾ
カリエンド、ギウゼッペ
Original Assignee
アンタイブ ホールディングス インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンタイブ ホールディングス インク． filed Critical アンタイブ ホールディングス インク．
Publication of JP2009543811A publication Critical patent/JP2009543811A/ja
Publication of JP2009543811A5 publication Critical patent/JP2009543811A5/ja
Application granted granted Critical
Publication of JP5529534B2 publication Critical patent/JP5529534B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
JP2009519765A 2006-07-18 2007-07-18 ４−ヒドロキシチオベンズアミド薬剤誘導体 Expired - Fee Related JP5529534B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80763906P 2006-07-18 2006-07-18
US60/807,639 2006-07-18
US88718807P 2007-01-30 2007-01-30
US60/887,188 2007-01-30
PCT/CA2007/001273 WO2008009118A1 (en) 2006-07-18 2007-07-18 4-hydroxythiobenzamide derivatives of drugs

Publications (3)

Publication Number Publication Date
JP2009543811A JP2009543811A (ja) 2009-12-10
JP2009543811A5 JP2009543811A5 (https=) 2010-12-16
JP5529534B2 true JP5529534B2 (ja) 2014-06-25

Family

ID=38956479

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009519765A Expired - Fee Related JP5529534B2 (ja) 2006-07-18 2007-07-18 ４−ヒドロキシチオベンズアミド薬剤誘導体
JP2009519769A Active JP5408719B2 (ja) 2006-07-18 2007-07-18 非ステロイド系抗炎症薬の硫化水素誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009519769A Active JP5408719B2 (ja) 2006-07-18 2007-07-18 非ステロイド系抗炎症薬の硫化水素誘導体

Country Status (17)

Country Link
US (1) US8314140B2 (https=)
EP (2) EP2041108B1 (https=)
JP (2) JP5529534B2 (https=)
KR (2) KR101450653B1 (https=)
AU (2) AU2007276679B2 (https=)
BR (2) BRPI0714330A2 (https=)
CA (2) CA2658429A1 (https=)
DK (1) DK2057139T3 (https=)
ES (1) ES2437223T3 (https=)
IL (2) IL196229A (https=)
MX (2) MX2009000749A (https=)
NO (2) NO20090764L (https=)
NZ (1) NZ573996A (https=)
PL (1) PL2057139T3 (https=)
PT (1) PT2057139E (https=)
RU (2) RU2468019C2 (https=)
WO (2) WO2008009118A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741359B2 (en) * 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
DK2057139T3 (da) * 2006-07-18 2013-11-18 Antibe Holdings Inc Hydrogensulfidderivater af non-steroide anti-inflammatoriske lægemidler
ITMI20080382A1 (it) * 2008-03-07 2009-09-08 Ctg Pharma S R L Composizioni farmaceutiche oculari
ITMI20081167A1 (it) * 2008-06-26 2009-12-27 Ctg Pharma S R L Composizioni farmaceutiche per il trattamento di malattie neurodegenerative
US8541396B2 (en) 2009-04-24 2013-09-24 National University Of Singapore Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent
WO2011053597A1 (en) * 2009-10-26 2011-05-05 The University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
US9242009B2 (en) 2012-07-17 2016-01-26 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
AU2017263574B2 (en) 2016-05-12 2022-11-17 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
WO2019094772A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l degraders and methods of treatment therewith
JP2021066660A (ja) * 2018-02-09 2021-04-30 アピオン・ジャパン有限会社 Ｔｉｒａｐ阻害剤
WO2022115952A1 (en) * 2020-12-03 2022-06-09 Antibe Therapeutics Inc. [1-(4-chloro-benzoyl)-5-methoxy-2-methyl-1h-indol-3-yl]-acetic acid 4-thiocarbamoyl-phenyl ester for the treatment of a viral infection
WO2023159296A1 (en) * 2022-02-28 2023-08-31 Antibe Therapeutics Inc. 4-thiocarbamoylphenyl 2-(4-oxophenyl)-phenyl propanoate for the treatment of pain associated with urologic chronic pelvic pain syndrome
GR1010438B (el) * 2022-03-21 2023-04-06 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", Φαρμακευτικες ενωσεις που βασιζονται στο συνδυασμο ενος ανταγωνιστη της ισταμινης και ενος δοτη υδροθειου για χρηση στην αντιμετωπιση του κνησμου
WO2025076616A1 (en) * 2023-10-11 2025-04-17 Antibe Therapeutics Inc. Polymorphic forms of otenaproxesul and compositions and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612252A (https=) * 1961-01-05
US4170654A (en) * 1976-02-13 1979-10-09 Merck & Co., Inc. Antihypertensive compositions containing N-heterocyclicalanines and α-
US4112095A (en) * 1976-10-07 1978-09-05 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents
US5214191A (en) * 1990-05-22 1993-05-25 Cortech, Inc. Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
US5663416A (en) * 1990-05-22 1997-09-02 Cortech Inc. Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1314184B1 (it) * 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US7638513B2 (en) * 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
EP1630164A1 (en) * 2004-08-31 2006-03-01 Expotrend Company SA Pyrazolopyrimidinones as phosphodiesterase inhibitors
EP1645288A1 (en) * 2004-10-07 2006-04-12 CTG Pharma S.r.l. New nuclear transcription factors regulators
CN2757375Y (zh) * 2004-11-25 2006-02-08 富士康(昆山)电脑接插件有限公司 电子卡连接器
EP1836160A1 (en) * 2004-12-24 2007-09-26 CTG Pharma S.r.l. Compounds for treating metabolic syndrome
CA2601381A1 (en) 2005-03-24 2006-09-28 Nycomed Gmbh 6-thioamide substituted benzimidazoles
ITMI20050680A1 (it) * 2005-04-18 2006-10-19 Ctg Pharma S R L Nuovi composti anti-infiammatori
US7498355B2 (en) 2005-05-27 2009-03-03 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
WO2006125293A1 (en) * 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
DK2057139T3 (da) * 2006-07-18 2013-11-18 Antibe Holdings Inc Hydrogensulfidderivater af non-steroide anti-inflammatoriske lægemidler

Also Published As

Publication number Publication date
EP2041108A1 (en) 2009-04-01
HK1131973A1 (en) 2010-02-12
JP2009543813A (ja) 2009-12-10
NO20090764L (no) 2009-04-16
BRPI0714466B8 (pt) 2021-05-25
PL2057139T3 (pl) 2014-06-30
AU2007276621A1 (en) 2008-01-24
AU2007276621B2 (en) 2013-08-01
WO2008009118A1 (en) 2008-01-24
RU2009105498A (ru) 2010-08-27
AU2007276679B2 (en) 2013-05-30
MX2009000750A (es) 2009-01-30
PT2057139E (pt) 2013-12-05
IL196229A (en) 2016-04-21
KR101495520B1 (ko) 2015-02-26
NZ573996A (en) 2012-03-30
CA2658429A1 (en) 2008-01-24
EP2057139B1 (en) 2013-09-04
BRPI0714466A2 (pt) 2013-05-14
DK2057139T3 (da) 2013-11-18
ES2437223T3 (es) 2014-01-09
MX2009000749A (es) 2009-01-30
BRPI0714330A2 (pt) 2013-05-07
CA2658433C (en) 2015-04-28
KR20090036115A (ko) 2009-04-13
EP2057139A1 (en) 2009-05-13
RU2009105491A (ru) 2010-08-27
IL196228A0 (en) 2009-09-22
JP2009543811A (ja) 2009-12-10
KR101450653B1 (ko) 2014-10-14
BRPI0714466B1 (pt) 2020-09-24
EP2057139A4 (en) 2010-09-15
NO342083B1 (no) 2018-03-19
RU2465271C2 (ru) 2012-10-27
KR20090040428A (ko) 2009-04-24
EP2041108A4 (en) 2010-12-29
RU2468019C2 (ru) 2012-11-27
AU2007276679A1 (en) 2008-01-24
HK1131125A1 (en) 2010-01-15
JP5408719B2 (ja) 2014-02-05
US8314140B2 (en) 2012-11-20
CA2658433A1 (en) 2008-01-24
WO2008009127A1 (en) 2008-01-24
NO20090763L (no) 2009-04-03
IL196229A0 (en) 2009-09-22
US20090306412A1 (en) 2009-12-10
EP2041108B1 (en) 2014-05-21

Similar Documents

Publication Publication Date Title
JP5529534B2 (ja) ４−ヒドロキシチオベンズアミド薬剤誘導体
AU778989B2 (en) Pharmaceutical compounds
AU781643B2 (en) Pharmaceutical compounds
CA2370425A1 (en) Pharmaceutical compounds
US20110098257A1 (en) Derivatives of 4- or 5-aminosalicylic acid
CN101490029B (zh) 药物的4-羟基硫代苯甲酰胺衍生物
AU2005202824B2 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130109

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130308

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140123

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140417

R150 Certificate of patent or registration of utility model

Ref document number: 5529534

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees